By J. Peratur. Montana State University-Bozeman.
Celecoxib 200 mg and diclofenac 50 mg had similar effects on pain after 1 year in 925 elderly 157 patients with osteoarthritis of the knee and/or hip (mean age of 71 years) generic 50 mg clomiphene overnight delivery women's health clinic vineland nj. Only 1 50 mg clomiphene otc women's health videos online, fair-quality, population-based retrospective cohort study evaluated the gastroprotective effects of adding a proton pump inhibitor in elderly patients taking celecoxib 109 (age ≥ 65 years). This study used data from the government of Quebec health services administrative databases and included 25 982 patients receiving celecoxib plus a proton pump inhibitor and 141 575 receiving celecoxib alone. Overall, the risk of hospitalization for a Nonsteroidal antiinflammatory drugs (NSAIDs) 33 of 72 Final Report Update 4 Drug Effectiveness Review Project perforated or bleeding ulcer was significantly reduced with celecoxib plus a proton pump inhibitor compared with celecoxib alone (adjusted hazard ratio, 0. However, additional subgroup analyses based on age found that gastroprotective advantage of adding a proton pump inhibitor was limited to patients aged 75 years or greater (adjusted hazard ratio, 0. In patients aged 66 to 74 years, there was no significant difference in gastrointestinal hospitalization risk between those receiving celecoxib plus a proton pump inhibitor and those receiving celecoxib alone (adjusted hazard ratio, 0. Two retrospective cohort studies evaluated the comparative gastrointestinal harms of receiving celecoxib alone compared with receiving a nonselective NSAID plus an antiulcer 98, 109 medication in the elderly. The first study used administrative healthcare databases from Ontario, Canada and found a significantly higher risk of upper gastrointestinal hemorrhage in elderly patients (age ≥ 66 years) given diclofenac plus misoprostol (N=5087) compared with 98 those given celecoxib (N=18 908) (relative risk 3. Alternatively, the 109 second study involved elderly adults from Quebec, Canada (described above), and evaluated a broader outcome (i. The comparative harms of celecoxib and nonselective NSAIDs in the elderly were 157 159 evaluated in 1 randomized controlled trial and 1 cohort study. In a fair-quality randomized controlled trial of 925 elderly patients with osteoarthritis of the knee and/or hip, compared with diclofenac 50 mg, 1 year of treatment with celecoxib 200 mg resulted in significantly lower rates of cardiovascular and renal adverse events (aggravated hypertension, edema, cardiac failure; 15% compared with 21%, P=0. The cohort study used prescription and health care claims data to evaluate 159 cardiovascular disease risk in elderly Pennsylvania Medicare beneficiaries (age ≥ 80 years). Finally, one retrospective cohort study evaluated the comparative cardiovascular risks of nonselective NSAIDs compared with nonuse in the elderly population of Ontario, Canada using 158 data from administrative healthcare databases. Celecoxib was associated with a neutral effect 158 on risk of admission for heart failure relative to nonuse (relative risk, 1. The effects of celecoxib on pain were also comparable to those of diclofenac when used concomitantly with angiotensin-converting enzyme inhibitors in a small study of all black or 160 Hispanic patients. Concomitant anticoagulant or aspirin use Concomitant anticoagulants Randomized controlled trial evidence was limited to 1 small, fair-quality, crossover trial that evaluated how celecoxib and codeine compared in their potentiation of the anticoagulant effects Nonsteroidal antiinflammatory drugs (NSAIDs) 34 of 72 Final Report Update 4 Drug Effectiveness Review Project 161 of warfarin in 15 patients with osteoarthritis. Results from this trial found no significant changes in the mean international normalized ratio values after 5 weeks of either celecoxib or codeine therapy. Only 1 patient experienced an episode of excessive anticoagulation (international normalized ratio, 4. The only evidence regarding the comparative safety of nonselective NSAIDs relative to celecoxib or partially selective NSAIDs when used concomitantly with anticoagulants was 162, 163 available from 2 small observational studies and was inconclusive due to flaws in design. Concomitant aspirin In patients receiving aspirin and who required ongoing NSAID therapy for osteoarthritis, we only found 1 trial (N=1045) designed to compare celecoxib alone to a nonselective NSAID plus 106 a proton pump inhibitor to reduce endoscopic ulcer rates. The daily dosage of aspirin was 81 mg in 89% of the patients and 325 mg in 11% of patients. After 12 weeks, the use of celecoxib 200 mg or naproxen 500 mg twice daily plus lansoprazole 30 mg daily resulted in similar rates of endoscopically confirmed gastroduodenal ulcers (20. The only other evidence of the comparative safety of NSAIDs when used in combination with aspirin came from a systematic review that conducted subgroup analyses according to the use of low-dose aspirin (325 mg or less) and found that both celecoxib 33 and nonselective NSAIDs were associated with significant increases in endoscopic ulcer rates. In a 2003 fair-quality case-control study of patients with known cardiovascular disease, risk of overall mortality (adjusted hazard ratio, 1. However, this study was small and did not control for potentially important confounders. Two subsequent fair-quality observational studies, using more broadly defined populations from the 165 93 UK GPRD and QRESEARCH databases, found that the risk of myocardial infarction was not significantly different in users of aspirin, with or without NSAIDs. Comorbidities In a good-quality randomized controlled trial of very high risk patients with a recent gastrointestinal bleed (N=273), the 13-month cumulative incidence of recurrent ulcer bleeding was significantly lower for celecoxib 200 mg plus esomeprazole 20 mg (0%) compared with celecoxib 200 mg alone (8. In 2 shorter-term randomized controlled trials comparing celecoxib to a nonselective NSAID plus a proton pump inhibitor in very high-risk patients with a recent gastrointestinal bleed, there were no statistically significant differences in recurrent ulcer bleeding (mean rate at 6 months: 4. However, rates of rebleeding were high with either intervention. A Danish Nonsteroidal antiinflammatory drugs (NSAIDs) 35 of 72 Final Report Update 4 Drug Effectiveness Review Project population-based case-control study of patients with previous gastrointestinal diseases found celecoxib was not associated with higher risks of upper gastrointestinal bleeding relative to 166 nonuse (odds ratio, 1. No trials were identified that evaluated the effects of celecoxib or NSAIDs on cardiovascular and cardiorenal events specifically in high-risk patients. One observational study found that patients who were prescribed celecoxib had lower rates of death and recurrent congestive heart failure when compared with patients who were prescribed nonselective 167 NSAIDs. SUMMARY The main findings of this review are summarized in Table 6 below. Little evidence on the comparative effectiveness of NSAIDs was truly effectiveness or “real world” – while some trials evaluated longer-term (>6-12 months) and real life (symptoms, clinical ulcers, functional status, myocardial infarctions, pain relief) outcomes, none were conducted in primary care or office- based setting or used broad enrollment criteria. For efficacy outcomes, there was high-strength evidence that there are no significant differences between oral NSAIDs. For comparisons among different topical diclofenac products, only low-strength, indirect evidence was available indicating that diclofenac 1. With regard to gastrointestinal adverse events, there was high-strength evidence that celecoxib seemed to offer a short-term advantage over nonselective NSAIDs, but this has not been conclusively demonstrated in longer-term studies.
Two additional studies of college student misuse of ADHD medications were found cheap clomiphene 50 mg with amex menstrual excessive bleeding. A study using a web-based survey tool to study students at Duke University and the University of North Carolina on various aspects of drug and alcohol misuse included questions on ADHD medication 336 misuse discount 25mg clomiphene otc menstruation journal. While 115 students reported having a drug prescribed to treat their ADHD, and responded to questions about misuse, the survey did not identify what the drugs being taken were. Similar to the studies discussed above, 31% reported misusing the drug (e. A small study of 66 adults prescribed methylphenidate found that 29% reported inappropriate use during the past month, with 84% using it orally, 74% using it nasally, and 11% 334 smoking it. Regression analysis indicated that misuse of methylphenidate was associated with illicit use of cocaine or amphetamines. This was a very small study, however, and such regression analyses should be interpreted with caution. A study of the Texas Poison Control Network revealed that 8. The database did not record the formulation of methylphenidate involved, although they report that the number of calls regarding methylphenidate had reduced during 1998 to 2000, then increased during 2001 to 2004. In looking at the evidence on diversion of these stimulants, the systematic review found that among children up through high school aged, 15% to 24% gave them away, 7% to 19% sold them, and 4% to 6% had them stolen at some time in the past. Among college students, 3 studies reported rates of diversion with widely varying rates reported. The lowest rate found in the systematic review, 23% to 29% had been asked to give, to trade, or to sell their ADHD 333 medications to another student. A web-based survey tool used to study students at Duke University and the University of North Carolina on various aspects of drug and alcohol misuse included questions on ADHD medication diversion, and rates of diversion among 115 students who had a drug prescribed to treat their ADHD were found to be higher. Fifty-six percent had been asked to sell their ADHD medications and 26% reported either giving or selling their 336 medications to another student. Another survey study of college students evaluated responses of 483 students with a prescription for any medication. This group of students had the highest rate of diverting ADHD medication at 61. The highest rate of diversion was reported with amphetamine/dextroamphetamine (70. Rates did not differ much between methylphenidate and extended-release methylphenidate (no formulation specified, 37% compared with 39. Data on sharing compared with selling medications were not stratified by type. In a small study of 66 adults prescribed methylphenidate, 44% reported diverting their medication to someone else, 334 with 97% giving it away, 17% selling it, and 14% doing both. Regression analyses indicated that diversion was associated with younger age both at the time of the survey and at the time methylphenidate was first prescribed. This was a very small study, however, and such regression analyses should be interpreted with caution. Attention deficit hyperactivity disorder 100 of 200 Final Update 4 Report Drug Effectiveness Review Project Reinforcing effects of ADHD medications We found 2 very small studies (1 in 5 children with ADHD, 1 in 10 adults with ADHD) that used 339, 340 a choice procedure as a proxy measurement of abuse potential. The logic behind this is that choice of 1 treatment over another may be reflective of the reinforcing effects of a drug, which is often considered to be predictive of abuse potential. The trials involved short-term administration of blinded drug (sampling days) and then allowing them to choose their preferred condition on other days (choice days). In the adult study, ADHD symptom improvement was self-assessed using a 5-point scale (1=“not effective” and 5=“extremely effective”). The main findings were that Immediate-release methylphenidate was chosen significantly more often than placebo (50% compared with 32. Based on these findings, authors concluded that the higher methylphenidate preference demonstrated by these patients was more reflective of therapeutic efficacy rather than abuse potential. In the study of children, effectiveness was measured in a variety of ways, none of which were standard ADHD rating scales. While the study found a higher rate of preference with immediate-release methylphenidate, the findings are not conclusive because the effectiveness data either showed no effect of methylphenidate or what was called an idiosyncratic response (no pattern identifiable). In addition, for both of these studies we feel that because the order of condition was not randomized and the sample sizes were so small, the studies should be considered exploratory only. Are there subgroups of patients based on demographics (age, racial groups, gender, and ethnicity), other medications, or comorbidities for which one pharmacologic treatment is more effective or associated with fewer adverse events? ADHD subtypes, comorbidities, and race or ethnicity were not recorded in most randomized controlled trials and observational studies. For example, only one-quarter of all studies of school- aged children reported ADHD subtype prevalence rates.
Cerebrospinal fluid analy- sis may be necessary if there is a suspicion of infection with purchase clomiphene 25 mg without a prescription menopause refers to, for example buy discount clomiphene 25 mg online menstrual and ovulation calendar, CMV or syphilis. Sural nerve and muscle biopsy may be necessary only in atypical cases – for instance, painful DSSP with a high CD4 cell count and low viral load and without neurotoxic medication or other risk factors. Table 4 gives some recommendations for clinical practice. Occasionally, patients report complaints of burning feet, aches, pain and tingling but clinical examination and nerve conduction studies are unremarkable. In these cases symptoms might be due to an isolated small fiber neuropathy exclusively affect- ing the small unmyelinated vegetative nerve fibers. Diagnosis requires a punch skin biopsy with histological assessment of intraepidermal nerve fiber density or pain- related evoked potential conduction testing (Obermann 2007). Intravenous immunoglobulins and plasmapheresis have proven effective in the therapy of AIDP. In clini- cal trials on the treatment of CIDP, no difference in the efficacy of immunoglobu- lins, plasmapheresis or corticosteroids has been shown. However, an individual patient may only respond to one of the three options. In patients who only respond to higher dosages of corticosteroids, other immunosuppressive agents such as aza- thioprine, low dose weekly methotrexate or cyclosporine may replace long-term steroid therapy. We have seen CIDP patients who were in partial remission after tem- porary steroid therapy and who have remained stable for years with ART alone. In medication-related neuropathy the offending agent needs to be withdrawn. The intake of 2 g L-acetylcarnitine significantly reduced pain in HIV patients with neurotoxic neuropathy (Youle 2007). ART might improve the function of sensory nerves in a few cases, and therefore starting ART or optimizing a current ART should be considered in newly diagnosed DSSP. In most cases the neuropathic symp- toms still persist. Symptomatic treatment is directed at irritative symptoms such as pain and paresthesia. It is not effective against deficits of nerve function including sensory loss or weakness. The agents listed in Table 6 are recommended because they have proven useful in daily practice and because they interfere only slightly and in a predictable way with ART. A controlled study showed that lamotrigine was effective in reducing the symp- toms of neurotoxic neuropathy (Simpson 2003). The drug is well tolerated if one adheres to the slow dose escalation regimen and stops treatment or reduces the dose when a skin reaction occurs. In a small study, gabapentin was shown to be effective in reducing DSSP-induced pain (Hahn 2004). The advantages of this agent are good tolerability and lack of interference with ART. Pregabalin, an anticonvulsant drug similar to gabapentin, effectively relieves pain in studies of patients with painful dia- betic peripheral neuropathy (Rosenstock 2004). Like gabapentin, it does not inter- fere with ART and is well tolerated. It is commonly used in DSSP, although a recent trial in HIV patients did not show efficacy (Simpson 2010). The tricyclic antidepressants amitriptyline and nortriptyline both have significant anticholinergic side effects. The dose necessary for reducing neuropathic pain is in the same range as for treating depression and many patients can not tolerate these dosages. However, lower dosages have proved ineffective in DSSP. We use this agent with good success rates, although clinical trials for its use in HIV-associated neuropathy are lacking. The antidepressant dulox- etine, a serotonin-norepinephrine reuptake inhibitor, has been approved for the treat- ment of painful diabetic neuropathy. In our experience it is also useful in reducing pain in DSSP and toxic neuropathy in HIV+ patients. The anticonvulsant carba- mazepine is widely used for the treatment of neuropathic pain. However, it induces some enzymes of the CYP450 system and interferes significantly with ART.
For the raising VWF levels or with other hemostatic therapies in oral cavity most refractory cases or for those women who no longer wish to procedures buy 100mg clomiphene visa womens health 2 coffee. Surgery/procedure prophylaxis using VWF concentrate therapy2 Duration of Procedure Loading dose Maintenance dose Monitoring goals treatment Major procedures Cardiothoracic surgery 40-60 RCo U/kg 20-40 RCo U/kg every 8-24 h; Peak RCo 100 IU/dL and 200 IU/dL; 7-14 d Cesarean section consider alternating with trough RCo 50 IU/dL; peak FVIII:C Craniotomy DDAVP in later days 100 % and 250%; trough FVIII:C 50% Open abdominal surgery Minor procedures Biopsy: breast buy clomiphene 25mg with mastercard womens health big book of yoga, cervical, lymph 30-60 RCo U/kg 20-40 RCo U/kg every 12-48 Peak RCo 100 IU/dL and 200 IU/dL; 1-5 d node h; often ﬁbrinolytic inhibitor trough RCo 50 IU/dL; peak FVIII:C Complex dental extractions or for 7-10 d if oral cavity; 100% and 250%; trough FVIII:C gingival surgery consider alternating with 50% Central line placement DDAVP in later days Laparoscopic procedures Other uncomplicated procedures Cardiac catheterization 20-40 RCo U/kg No factor; often ﬁbrinolytic Typically not measured if prior Outside of oral cavity, Endoscopy without biopsy inhibitor for 7-10 d if oral experience with that patient produced often single Liver biopsy cavity; consider follow-up RCo 50 IU/dL or FVIII:C 50% treatment DDAVP Simple dental extractions 538 American Society of Hematology Table 5. Adjunctive hemostatic agents Generic name Form Dosing Comments Aminocaproic acid Oral suspension 250 mg/mL 50-100 mg/kg orally every 6 h Avoid if hematuria present; use with caution 500 mg or 1000 mg tablet 50-100 mg/kg orally every 6 h with disseminated intravascular 250 mg/mL IV Up to 1 g/h continuous infusion coagulation; can cause nausea Tranexamic acid 650 mg tablets 1300 mg orally every 8 h 5d Avoid if hematuria present; avoid combining menses with prothrombin complex concentrates Pediatric patients: 15-20 mg/kg every 8 h 5d 100 mg/mL IV 10 mg/kg IV every 6-8 h Tisseel sealant (human thrombin, 2 mL, 4 mL, 10 mL syringe Apply a thin layer to wound Made from human plasma ﬁbrinogen, bovine aprotinin) Topical bovine thrombin Spray solution Apply a thin layer to wound Thrombosis; can cause antibodies to Reconstituted to 100-1000 units/mL thrombin, Factor V Recombinant thrombin Spray solution Apply a thin later to wound Thrombosis; rare allergic reaction Reconstituted to 1000 units/mL Informationprovidedisfromtheproductpackageinserts. Pregnancy and delivery necessitating VWF factor concentrates at delivery and with invasive For best outcomes, pregnancies in a woman with VWD should be procedures during pregnancy. Because VWF levels rise throughout pregnancy, binding the patient is adequately informed about her risks of hemorrhage of the mutant VWF to platelets can increase platelet clearance to before and after delivery and the methods of pain control available further depress platelet counts. Her infant is also at risk for side effects from the mother’s counts to fall to levels of 20 000/ L or less, creating a worse treatment and there is the possibility of the infant inheriting this situation than before pregnancy. FVIII:C and during pregnancy, at the time of delivery, and into the postpartum VWF:RCo should be checked before any invasive procedures and in period to prevent hemorrhage. In 2005, published results of years of prophylaxis in a prophylaxis is indicated during pregnancy and at delivery. Regional Swedish cohort of 35 patients revealed its success at preventing anesthesia can be permitted with VWF:RCo and FVIII:C levels joint disease if treatment is begun at an early age and also reduced 21 the occurrence of epistaxis and gastrointestinal bleeding. In women known before pregnancy to have VWD, the adjusted odds ratio of primary prompted the formation of the von Willebrand Disease Prophylaxis postpartum hemorrhage was 3. The most common reasons for prophylaxis baseline levels by day 14. Women should be counseled to report any increase patients with type 2A, 8 patients with type 2B, and 2 patients with in postpartum bleeding swiftly to their hematologist to obtain type 2M VWD. The greatest effect of the 1-3 times weekly infusions treatment with either DDAVP or factor supplements to prevent of 40-60 RCo U/kg VWF concentrates was the reduction in joint signiﬁcant hemorrhage. Other options include ﬁbrinolytic inhibi- bleeding of nearly 90%. Lactating mothers should exercise some caution with medica- of epistaxis, intensity of heavy menstrual bleeding, and, in the older tions. Little is reported about the excretion of DDAVP in breast milk populations, gastrointestinal bleeding. Gastrointestinal bleeding in bleeding disorder patients. Tranexamic acid is present in concen- required higher doses closer to 60 RCo U/kg of VWF concentrate trations 1/100 of the serum level (per package insert) and its effect for improvement. There have been no thrombotic complications of on infants is unknown. A rise in VWF:Ag levels is not always spontaneous hemorrhage who would beneﬁt from a prophylaxis accompanied by an adequate rise in VWF:RCo activity, often regimen. Further studies anaphylactic reactions with exposure. Treatment of these patients can be Gene therapy quite challenging and this topic has been reviewed recently. Combining both rFVIIa and rFVIII was successful in enabling delivery of an infant and recovery of the mother after childbirth. As we progress in understanding the basis for quantita- ance induction similar to that seen with inhibitors to FVIII has been tive deﬁciencies in type 1 disease, we may be able to increase reported. Newer treatment strategies may focus on enhancing endogenous produc- Future therapies tion and release or prolonging the half-life of VWF infusions for Recombinant VWF prolonged efﬁcacy and convenience of patients. Recombinant FVIII and factor IX have been available for many years, but only recently has rVWF been studied in clinical trials. In a Acknowledgments pharmacokinetic and safety study, rVWF-rFVIII compared favor- The authors thank our hemostasis staff for their tireless efforts in ably to plasma-derived VWF-FVIII. Recovery, as measured by caring for bleeding disorder patients: Julie Thomas, Kelly Dawson, VWF:RCo activity assay, was quite similar, but rVWF-rFVIII Shelley Ploch, Johnna Oleis, Lyndsey Rollins, Pamela Krueger, and infusions produced a slightly lower VWF:Ag level, demonstrating a Kim Blittle. This higher ratio of activity is due to the increased Disclosures relative amount of ultra-large-molecular weight multimers in the Conﬂict-of-interest disclosures: A. In theory, this could lead ticals, and the American Board of Internal Medicine and has to thrombotic complications, but studies of the patient plasma received research funding from NovoNordisk. Off-label drug stabilization of endogenous FVIII by the rVWF that produced a use: Oral contraceptives for VWD. This may allow the infusion of only rVWF if there is no immediate need for FVIII:C to avoid the Correspondence excessive rise in FVIII:C when plasma-derived concentrates are Anne T. Neff, MD, Vanderbilt University; Phone: (615)936-0381; infused for several doses. Acute bleeding situations in type 3 Fax: (615)343-3694; email: anne.
9 of 10 - Review by J. Peratur
Votes: 231 votes
Total customer reviews: 231